<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00809</drugbank-id>
  <drugbank-id>APRD00287</drugbank-id>
  <name>Tropicamide</name>
  <description>One of the muscarinic antagonists with pharmacologic action similar to atropine and used mainly as an ophthalmic parasympatholytic or mydriatic. [PubChem]</description>
  <cas-number>1508-75-4</cas-number>
  <unii>N0A3Z5XTC6</unii>
  <average-mass>284.3529</average-mass>
  <monoisotopic-mass>284.152477894</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye.</indication>
  <pharmacodynamics>Tropicamide belongs to the group of medicines called anti-muscarinics. Tropicamide blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. By blocking these receptors, tropicamide produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia). Tropicamide is given as eye drops to dilate the pupil and relax the lens so that eye examinations can be carried out thoroughly.</pharmacodynamics>
  <mechanism-of-action>Tropicamide binds to and blocks the receptors in the muscles of the eye (muscarinic receptor M4). Tropicamide acts by blocking the responses of the iris sphincter muscle to the iris and ciliary muscles to cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle.</mechanism-of-action>
  <toxicity>Overdose can casue dry mouth, blurred vision, photophobia, hallucinations and rapid/irregular pulse.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding>45%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.</description>
    <direct-parent>Phenylacetamides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Phenylacetamides</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Pyridines and derivatives</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylacetamide</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="german" coder="inn">Tropicamid</synonym>
    <synonym language="spanish" coder="inn">Tropicamida</synonym>
    <synonym language="english/french" coder="inn/usan">Tropicamide</synonym>
    <synonym language="latin" coder="inn">Tropicamidum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Diophenyl-T Solution</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023717</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minims Tropicamide 1%</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148536</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mydriacyl</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0998-0354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-04-01</started-marketing-on>
      <ended-marketing-on>2003-06-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA084305</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mydriacyl</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0998-0355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA084306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mydriacyl</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA084306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mydriacyl</name>
      <labeller>Alcon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00000981</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.5 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mydriacyl</name>
      <labeller>Alcon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00001007</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mydriatic-3</name>
      <labeller>Imprimis Njof Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71384-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mydriatic-4</name>
      <labeller>Imprimis Njof, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71384-632</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Odan-tropicamide</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00622885</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Odan-tropicamide</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00627704</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Paremyd</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA019261</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phenyltrope Oph Soln</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00629693</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-tropicamide Oph Sltn 1%</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00872946</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>R.O.-tropamide</name>
      <labeller>Richmond Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00896446</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-11</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-29</started-marketing-on>
      <ended-marketing-on>2005-06-30</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Henry Schein</labeller>
      <ndc-id/>
      <ndc-product-code>0404-7192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040315</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040315</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040315</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040067</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Sandoz Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61314-354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA084305</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Sandoz Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61314-355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA084306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA207524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023679</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tropicamide</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023660</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.5 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tropicamide 1% - Liq Oph 10mg/ml</name>
      <labeller>Rivex Ophthalmics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02212919</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-09-15</started-marketing-on>
      <ended-marketing-on>2003-07-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Better</name>
      <company>Taiwan Biotech</company>
    </international-brand>
    <international-brand>
      <name>Camide</name>
      <company>Ibn Sina</company>
    </international-brand>
    <international-brand>
      <name>Ciclomidrin</name>
      <company>Latinofarma</company>
    </international-brand>
    <international-brand>
      <name>Dilate</name>
      <company>Incepta</company>
    </international-brand>
    <international-brand>
      <name>Eyetrop</name>
      <company>Apex</company>
    </international-brand>
    <international-brand>
      <name>Losemin</name>
      <company>Oasis</company>
    </international-brand>
    <international-brand>
      <name>Midax</name>
      <company>Rompharm</company>
    </international-brand>
    <international-brand>
      <name>Midric</name>
      <company>Sanbe</company>
    </international-brand>
    <international-brand>
      <name>Minims Tropicamide</name>
      <company>Bausch &amp; Lomb</company>
    </international-brand>
    <international-brand>
      <name>Mydral</name>
      <company>Ocusoft</company>
    </international-brand>
    <international-brand>
      <name>Mydramide</name>
      <company>Fischer</company>
    </international-brand>
    <international-brand>
      <name>Mydriaticum</name>
      <company>Ciba Vision</company>
    </international-brand>
    <international-brand>
      <name>Mydricol</name>
      <company>Unimed</company>
    </international-brand>
    <international-brand>
      <name>Ocu-Tropic</name>
      <company>Ocumed</company>
    </international-brand>
    <international-brand>
      <name>Tropicacyl</name>
      <company>Akorn</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Paremyd</name>
      <ingredients>Hydroxyamphetamine + Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriatic-3</name>
      <ingredients>Cyclopentolate + Phenylephrine + Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriatic-4</name>
      <ingredients>Ketorolac + Phenylephrine + Proparacaine + Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriacyl</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriacyl</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriacyl</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>PMS-tropicamide Oph Sltn 1%</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>R.O.-tropamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide 1% - Liq Oph 10mg/ml</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Minims Tropicamide 1%</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriacyl</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Mydriacyl</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Odan-tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Odan-tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Tropicamide</name>
      <ingredients>Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Diophenyl-T Solution</name>
      <ingredients>Phenylephrine + Tropicamide</ingredients>
    </mixture>
    <mixture>
      <name>Phenyltrope Oph Soln</name>
      <ingredients>Phenylephrine + Tropicamide</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Accutome Inc.</name>
      <url>http://www.accutome.com</url>
    </packager>
    <packager>
      <name>Akorn Inc.</name>
      <url>http://www.akorn.com</url>
    </packager>
    <packager>
      <name>Alcon Laboratories</name>
      <url>http://www.alcon.com</url>
    </packager>
    <packager>
      <name>Bausch &amp; Lomb Inc.</name>
      <url>http://www.bausch.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Eye Care and Cure Corp.</name>
      <url>http://www.eyecareandcure.com</url>
    </packager>
    <packager>
      <name>Eye Supply Usa Inc.</name>
      <url>http://www.eyesupplyusa.com</url>
    </packager>
    <packager>
      <name>Falcon Pharmaceuticals Ltd.</name>
      <url>http://www.falconpharma.com</url>
    </packager>
    <packager>
      <name>Medical Ophthalmics</name>
      <url/>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Wilson Ophthalmic Corp.</name>
      <url>http://www.hilco.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Alcon laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Pharmafair inc</manufacturer>
    <manufacturer generic="false" url="">Akorn inc</manufacturer>
    <manufacturer generic="true" url="">Alcon universal ltd</manufacturer>
    <manufacturer generic="true" url="">Bausch and lomb pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Miza pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Tropicamide 0.5% eye drops</description>
      <cost currency="USD">1.06</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Mydriacyl 1 % Solution</description>
      <cost currency="USD">1.21</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Paremyd eye drops</description>
      <cost currency="USD">1.28</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Tropicamide 1% eye drops</description>
      <cost currency="USD">2.52</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Mydriacyl 1% eye drops</description>
      <cost currency="USD">5.54</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Tropicamide 1% Solution 2ml Bottle</description>
      <cost currency="USD">7.99</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Tropicamide 1% Solution 3ml Bottle</description>
      <cost currency="USD">13.99</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Mydriacyl 1% Solution 3ml Bottle</description>
      <cost currency="USD">17.28</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Tropicamide 1% Solution 15ml Bottle</description>
      <cost currency="USD">17.75</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Tropicamide 0.5% Solution 15ml Bottle</description>
      <cost currency="USD">17.99</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Mydriacyl 1% Solution 15ml Bottle</description>
      <cost currency="USD">59.84</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Tropicamide powder</description>
      <cost currency="USD">72.83</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Tropicacyl 0.5% eye drops</description>
      <cost currency="USD">0.67</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Tropicacyl 1% eye drops</description>
      <cost currency="USD">0.71</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Mydriacyl 0.5 % Solution</description>
      <cost currency="USD">0.94</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anticholinergic Agents</category>
      <mesh-id>D018680</mesh-id>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agents</category>
      <mesh-id>D018678</mesh-id>
    </category>
    <category>
      <category>Muscarinic Antagonists</category>
      <mesh-id>D018727</mesh-id>
    </category>
    <category>
      <category>Mydriatics</category>
      <mesh-id>D009184</mesh-id>
    </category>
    <category>
      <category>Mydriatics and Cycloplegics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Pyridines</category>
      <mesh-id>D011725</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>0.5 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>1 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01FA06">
      <level code="S01FA">Anticholinergics</level>
      <level code="S01F">MYDRIATICS AND CYCLOPLEGICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="S01FA56">
      <level code="S01FA">Anticholinergics</level>
      <level code="S01F">MYDRIATICS AND CYCLOPLEGICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:24.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00809.pdf?1265922742</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The risk or severity of adverse effects can be increased when Trospium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of adverse effects can be increased when Butalbital is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Benzatropine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of adverse effects can be increased when Disopyramide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The risk or severity of adverse effects can be increased when Talbutal is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Amitriptyline is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The risk or severity of adverse effects can be increased when Ipratropium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of adverse effects can be increased when Methadone is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of adverse effects can be increased when Olanzapine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The risk or severity of adverse effects can be increased when Metixene is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The risk or severity of adverse effects can be increased when Terfenadine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of adverse effects can be increased when Buclizine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Clozapine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The risk or severity of adverse effects can be increased when Doxylamine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Procyclidine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The risk or severity of adverse effects can be increased when Profenamine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Secobarbital is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of adverse effects can be increased when Promazine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of adverse effects can be increased when Imipramine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The risk or severity of adverse effects can be increased when Metharbital is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Fluoxetine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The risk or severity of adverse effects can be increased when Darifenacin is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Nortriptyline is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of adverse effects can be increased when Amoxapine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of adverse effects can be increased when Atropine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The risk or severity of adverse effects can be increased when Thiopental is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The risk or severity of adverse effects can be increased when Nicardipine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of adverse effects can be increased when Paroxetine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Procaine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of adverse effects can be increased when Rocuronium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Isoflurane is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The risk or severity of adverse effects can be increased when Benzquinamide is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of adverse effects can be increased when Clidinium is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The risk or severity of adverse effects can be increased when Propiomazine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The risk or severity of adverse effects can be increased when Propantheline is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The risk or severity of adverse effects can be increased when Primidone is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Amantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Cyclopentolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Chloroprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Barbituric acid derivative.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Revefenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The therapeutic efficacy of Tegaserod can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The therapeutic efficacy of Zinc can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The therapeutic efficacy of Sorbitol can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The therapeutic efficacy of Dantron can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The therapeutic efficacy of Prucalopride can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The therapeutic efficacy of Emodin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The therapeutic efficacy of Glycerin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The therapeutic efficacy of Mineral oil can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The therapeutic efficacy of Docusate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The therapeutic efficacy of Plantago seed can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The therapeutic efficacy of Castor oil can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The therapeutic efficacy of Sennosides can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The therapeutic efficacy of Lactitol can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The therapeutic efficacy of Plecanatide can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The therapeutic efficacy of Deacetylbisacodyl can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14502</drugbank-id>
      <name>Sodium phosphate, dibasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The therapeutic efficacy of Magnesium can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The therapeutic efficacy of Konjac mannan can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The therapeutic efficacy of Alloin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The therapeutic efficacy of Tropicamide can be decreased when used in combination with Donepezil.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.42</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.75e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.38</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tropicamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>284.3529</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>284.152477894</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C17H20N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BGDKAVGWHJFAGW-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>53.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>82.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>29.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>15.18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>5.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>96.5 C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.3</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5843</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>9757</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5593</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505924</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00397</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5391</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>82371</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749389</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000345</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tropicamide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200604</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/tropicamide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000405</id>
      <name>Muscarinic acetylcholine receptor M4</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5677</ref-id>
            <pubmed-id>17594079</pubmed-id>
            <citation>Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08173" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M4</name>
        <general-function>Guanyl-nucleotide exchange factor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.</specific-function>
        <gene-name>CHRM4</gene-name>
        <locus>11p12-p11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>32-54
69-89
107-128
149-171
194-216
402-422
437-456</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.34</theoretical-pi>
        <molecular-weight>53048.65</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1953</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M16405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>61970253</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>16</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>16</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010280|Muscarinic acetylcholine receptor M4
MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVN
RQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASV
MNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTV
PDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAK
TLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGS
ATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIV
PATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMV
LVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010281|Muscarinic acetylcholine receptor M4 (CHRM4)
ATGGCCAACTTCACACCTGTCAATGGCAGCTCGGGCAATCAGTCCGTGCGCCTGGTCACG
TCATCATCCCACAATCGCTATGAGACGGTGGAAATGGTCTTCATTGCCACAGTGACAGGC
TCCCTGAGCCTGGTGACTGTCGTGGGCAACATCCTGGTGATGCTGTCCATCAAGGTCAAC
AGGCAGCTGCAGACAGTCAACAACTACTTCCTCTTCAGCCTGGCGTGTGCTGATCTCATC
ATAGGCGCCTTCTCCATGAACCTCTACACCGTGTACATCATCAAGGGCTACTGGCCCCTG
GGCGCCGTGGTCTGCGACCTGTGGCTGGCCCTGGACTACGTGGTGAGCAACGCCTCCGTC
ATGAACCTTCTCATCATCAGCTTTGACCGCTACTTCTGCGTCACCAAGCCTCTCACCTAC
CCTGCCCGGCGCACCACCAAGATGGCAGGCCTCATGATTGCTGCTGCCTGGGTACTGTCC
TTCGTGCTCTGGGCGCCTGCCATCTTGTTCTGGCAGTTTGTGGTGGGTAAGCGGACGGTG
CCCGACAACCAGTGCTTCATCCAGTTCCTGTCCAACCCAGCAGTGACCTTTGGCACAGCC
ATTGCTGCCTTCTACCTGCCTGTGGTCATCATGACGGTGCTGTACATCCACATCTCCCTG
GCCAGTCGCAGCCGAGTCCACAAGCACCGGCCCGAGGGCCCGAAGGAGAAGAAAGCCAAG
ACGCTGGCCTTCCTCAAGAGCCCACTAATGAAGCAGAGCGTCAAGAAGCCCCCGCCCGGG
GAGGCCGCCCGGGAGGAGCTGCGCAATGGCAAGCTGGAGGAGGCCCCCCCGCCAGCGCTG
CCACCGCCACCGCGCCCCGTGGCTGATAAGGACACTTCCAATGAGTCCAGCTCAGGCAGT
GCCACCCAGAACACCAAGGAACGCCCAGCCACAGAGCTGTCCACCACAGAGGCCACCACG
CCCGCCATGCCCGCCCCTCCCCTGCAGCCGCGGGCCCTCAACCCAGCCTCCAGATGGTCC
AAGATCCAGATTGTGACGAAGCAGACAGGCAATGAGTGTGTGACAGCCATTGAGATTGTG
CCTGCCACGCCGGCTGGCATGCGCCCTGCGGCCAACGTGGCCCGCAAGTTCGCCAGCATC
GCTCGCAACCAGGTGCGCAAGAAGCGGCAGATGGCGGCCCGGGAGCGCAAAGTGACACGA
ACGATCTTTGCCATTCTGCTAGCCTTCATCCTCACCTGGACGCCCTACAACGTCATGGTC
CTGGTGAACACCTTCTGCCAGAGCTGCATCCCTGACACGGTGTGGTCCATTGGCTACTGG
CTCTGCTACGTCAACAGCACCATCAACCCTGCCTGCTATGCTCTGTGCAACGCCACCTTT
AAAAAGACCTTCCGGCACCTGCTGCTGTGCCAGTATCGGAACATCGGCACTGCCAGGTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>guanyl-nucleotide exchange factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0000092</id>
      <name>Muscarinic acetylcholine receptor M1</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5677</ref-id>
            <pubmed-id>17594079</pubmed-id>
            <citation>Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11229" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M1</name>
        <general-function>Phosphatidylinositol phospholipase c activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.</specific-function>
        <gene-name>CHRM1</gene-name>
        <locus>11q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>25-47
62-82
100-121
142-164
187-209
367-387
402-421</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.67</theoretical-pi>
        <molecular-weight>51420.375</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1950</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X52068</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>34451</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>13</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>13</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11229</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000184|Muscarinic acetylcholine receptor M1
MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVN
NYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLIS
FDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYI
QFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSS
SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEV
VIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKE
KKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL
CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009929|Muscarinic acetylcholine receptor M1 (CHRM1)
ATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG
GGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG
ACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT
AACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC
CTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC
TGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC
TTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC
CGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC
ATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC
CAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT
GTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG
GAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC
TCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT
CGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG
GACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG
GTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG
AGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC
CAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG
AAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG
TACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG
GAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC
TGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA
CGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>entrainment of circadian clock</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of intracellular protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000560</id>
      <name>Muscarinic acetylcholine receptor M2</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5677</ref-id>
            <pubmed-id>17594079</pubmed-id>
            <citation>Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08172" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M2</name>
        <general-function>G-protein coupled acetylcholine receptor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.</specific-function>
        <gene-name>CHRM2</gene-name>
        <locus>7q31-q35</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>23-45
60-80
98-119
140-162
185-209
388-410
419-442</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.08</theoretical-pi>
        <molecular-weight>51714.605</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1951</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M16404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177990</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>14</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>14</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08172</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016133|Muscarinic acetylcholine receptor M2
MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY
FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD
RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF
FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI
VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE
ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI
VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT
VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016134|Muscarinic acetylcholine receptor M2 (CHRM2)
ATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA
TTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG
AACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC
TTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC
ACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA
GCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC
AGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA
GGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC
TTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT
TTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC
ATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC
AAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA
GTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC
CAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG
GAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA
ATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT
AAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT
AATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT
GTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC
CGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG
GCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT
GTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT
GCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG
AACATAGGCGCTACAAGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>symmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000045</id>
      <name>Muscarinic acetylcholine receptor M3</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5677</ref-id>
            <pubmed-id>17594079</pubmed-id>
            <citation>Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20309" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M3</name>
        <general-function>Receptor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.</specific-function>
        <gene-name>CHRM3</gene-name>
        <locus>1q43</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>68-91
105-130
143-164
185-206
230-252
492-514
527-546</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.62</theoretical-pi>
        <molecular-weight>66127.445</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1952</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X15266</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>15</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>15</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20309</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009898|Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009899|Muscarinic acetylcholine receptor M3 (CHRM3)
ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG
ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC
AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG
GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG
GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG
ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT
TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC
TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG
GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA
ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG
GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG
TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT
TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG
CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT
GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG
AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG
AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT
GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG
ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC
ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC
TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT
CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT
TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA
GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG
ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC
ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC
ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC
CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG
TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT
TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vascular smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>